ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$114.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$174.85M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $249.43M, a 198.38% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $156.23M, a 109.79% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$155.74M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $75.07M, a 17.59% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $91.09M, a 12.68% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $80.84M, a 57.85% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $191.77M, a 117.33% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$114.42M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | -$174.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $74.58M derived: sum of 2 quarters · filed 2026-02-12 | $230.80M derived: sum of 3 quarters · filed 2026-07-30 | $75.07M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $249.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $405.66M derived: sum of 2 quarters · filed 2026-07-30 | $249.92M 10-Q · filed 2025-10-30 | $187.81M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $156.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $490.00K 10-Q · filed 2026-07-30 | $26.41M 10-Q · filed 2025-07-31 | -$61.62M derived: sum of 3 quarters · filed 2026-07-30 | $21.98M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$155.74M 10-Q · filed 2025-05-01 | -$217.84M derived: sum of 2 quarters · filed 2026-02-12 | -$134.25M derived: sum of 3 quarters · filed 2026-02-12 | -$59.78M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-12-31 | -$62.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $21.49M derived: sum of 2 quarters · filed 2026-02-12 | $95.96M derived: sum of 3 quarters · filed 2026-02-12 | $91.09M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $83.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $158.06M derived: sum of 2 quarters · filed 2025-10-30 | $153.20M 10-Q · filed 2025-10-30 | $114.53M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-06-30 | $74.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $69.61M 10-Q · filed 2025-07-31 | $30.94M derived: sum of 3 quarters · filed 2026-02-12 | $149.68M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2024-03-31 | -$4.87M 10-Q · filed 2025-05-01 | -$43.53M derived: sum of 2 quarters · filed 2026-02-12 | $75.21M derived: sum of 3 quarters · filed 2026-02-12 | $157.95M derived: sum of 4 quarters · filed 2026-02-12 | |
| 2023-12-31 | -$38.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $80.07M derived: sum of 2 quarters · filed 2026-02-12 | $162.81M derived: sum of 3 quarters · filed 2026-02-12 | $80.84M 10-K · filed 2026-02-12 | |
| 2023-09-30 | $118.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $201.48M derived: sum of 2 quarters · filed 2024-10-31 | $119.51M 10-Q · filed 2024-10-31 | $222.12M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-06-30 | $82.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $766.00K 10-Q · filed 2024-08-01 | $103.38M derived: sum of 3 quarters · filed 2025-02-13 | $173.13M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2023-03-31 | -$81.97M 10-Q · filed 2024-05-02 | $20.64M derived: sum of 2 quarters · filed 2025-02-13 | $90.39M derived: sum of 3 quarters · filed 2025-02-13 | $158.53M derived: sum of 4 quarters · filed 2025-02-13 | |
| 2022-12-31 | $102.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $172.36M derived: sum of 2 quarters · filed 2025-02-13 | $240.50M derived: sum of 3 quarters · filed 2025-02-13 | $191.77M 10-K · filed 2025-02-13 | |
| 2022-09-30 | $69.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $137.89M derived: sum of 2 quarters · filed 2023-11-02 | $89.15M 10-Q · filed 2023-11-02 | $128.65M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-06-30 | $68.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $19.41M 10-Q · filed 2023-08-03 | $58.91M derived: sum of 3 quarters · filed 2024-02-15 | $105.27M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2022-03-31 | -$48.74M 10-Q · filed 2023-05-04 | -$9.23M derived: sum of 2 quarters · filed 2024-02-15 | $37.13M derived: sum of 3 quarters · filed 2024-02-15 | $106.08M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-12-31 | $39.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $85.87M derived: sum of 2 quarters · filed 2024-02-15 | $154.81M derived: sum of 3 quarters · filed 2024-02-15 | $88.24M 10-K · filed 2024-02-15 | |
| 2021-09-30 | $46.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $115.31M derived: sum of 2 quarters · filed 2022-10-27 | $48.74M 10-Q · filed 2022-10-27 | $116.91M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $68.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $2.37M 10-Q · filed 2022-07-28 | $70.54M derived: sum of 3 quarters · filed 2023-02-23 | $144.07M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$66.57M 10-Q · filed 2022-04-28 | $1.59M derived: sum of 2 quarters · filed 2023-02-23 | $75.12M derived: sum of 3 quarters · filed 2023-02-23 | $91.37M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $68.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $141.70M derived: sum of 2 quarters · filed 2023-02-23 | $157.95M derived: sum of 3 quarters · filed 2023-02-23 | $143.73M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $73.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $89.78M derived: sum of 2 quarters · filed 2021-10-28 | $75.56M 10-Q · filed 2021-10-28 | $110.55M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-06-30 | $16.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $2.04M 10-Q · filed 2021-08-03 | $37.02M derived: sum of 3 quarters · filed 2022-02-10 | $50.83M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-03-31 | -$14.21M 10-Q · filed 2021-04-29 | $20.77M derived: sum of 2 quarters · filed 2022-02-10 | $34.58M derived: sum of 3 quarters · filed 2022-02-10 | $102.47M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2019-12-31 | $34.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $48.80M derived: sum of 2 quarters · filed 2022-02-10 | $116.69M derived: sum of 3 quarters · filed 2022-02-10 | $92.35M 10-K · filed 2022-02-10 | |
| 2019-09-30 | $13.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $81.70M derived: sum of 2 quarters · filed 2020-11-05 | $57.37M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $67.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $43.56M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$24.33M 10-Q · filed 2020-05-06 | ||||
| 2018-12-31 | $74.83M 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | $26.63M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |